Pharma's Almanac TV
PA TV
Follow the Journey
Companies We've Met
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Current Issue
Archive
Reports
Biologics Pricing Report
Oral Solid Dose Market Report
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
By The Numbers
Viral Vector Manufacturing
12 Articles Available
Can't find what you're looking for? Try our
advanced search
.
Acquisition
Thermo Fisher Scientific Acquires Viral Vector Manufacturing Business from Novasep
PR-M11-20-035
Capacity Expansion
Emergent BioSolutions to Invest $75 Million in Canton Site and Expand Viral Vector and Gene Therapy Capability
PR-M06-20-NI-029
Capacity Expansion
Kite Announces Plans to Bolster Industry-Leading Cell Therapy Manufacturing Capabilities With New Viral Vector Facility
PR-M07-19-NI-043
Viral Vector Manufacturing
Accelerating The Development of Viral Vector Manufacturing Processes
PAP-Q2-2019-CL-009
AAV and LV Vectors
Supporting AAV and Lentiviral Vector Development and Commercialization
PAP-Q2-2019-CL-005
Viral Vector Manufacturing
$1.01 Billion Viral Vector Manufacturing - Global Market Outlook 2017-2026
PR-M04-19-NI-081
Acquistion
Thermo Fisher Scientific to Acquire Brammer Bio, a Leader in Viral Vector Manufacturing
PR-M03-19-NI-078
Viral Vectors
Preclinical to Nearly Commercial Virus and Viral Vector Manufacturing
PAP-Q1-2019-CL-020
Viral Vector Manufacturing
From Proof of Concept to Commercialization
PAP-Q4-18-CL-003
Cell and Gene Therapy
Analytical Methodologies Utilized in Therapeutic Viral Vector Manufacturing
PAP-Q3-18-CL-001
Viral Vector Manufacturing
The Future of the Viral Vector Manufacturing Market
PAO-M09-18-CL-003
Cell and Gene Therapy
Overcoming Raw Material and Supply Chain Challenges in Viral Vector Manufacturing
PAP-Q2-18-CL-011
